X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

Content Team by Content Team
21st February 2023
in Drug Development, Press Statements
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.  The foundation of the collaboration lies in the combination of Formosa’s APNTâ„¢ formulation platform with Eyenovia’s Optejet® delivery system.

Eyenovia’s Optejet® delivery platform for ocular therapeutics utilizes Microdose Array Print (MAPâ„¢) technology to deliver 6-8 microliters of drug product, consistent with the capacity of the tear film of the eye.  At less than 20% volume of that delivered by conventional eyedroppers, Optejet® reduces the risk of overdosing and unnecessary drug exposure.  Furthermore, the Optejet® action is both rapid and gentle, ensuring efficient and comfortable delivery to the ocular surface.

Formosa’s proprietary APNTâ„¢ formulation platform improves dissolution and bioavailability of active pharmaceutical ingredients via a mild and efficient particle size reduction technique optimized for topical, oral, or inhaler administration routes.  Resulting formulations have high uniformity, purity, and stability, thereby allowing the utilization of poorly soluble or extremely potent drug agents which otherwise may face insurmountable challenges in delivery and penetration to target tissues.

“We have assembled a large and growing body of evidence demonstrating the many benefits of Optejet®, including improved patient compliance and the achievement of therapeutic doses of medication with far less stress on the ocular surface than other forms of administration, such as standard eye drops,” stated Michael Rowe, Chief Executive Officer of Eyenovia. “Through this development collaboration, we not only gain access to Formosa’s proven ophthalmic formulation expertise for further development using Optejet®, but also its APNTâ„¢ formulation platform which opens up several new and large market indications for potential expansion of our own development pipeline. We look forward to a long and mutually beneficial partnership.”

“We are delighted to have this opportunity to explore new frontiers in ophthalmology in this collaboration with Eyenovia,” said Erick Co, Chief Executive Officer of Formosa Pharmaceuticals.  “Each company’s proprietary technology enables the efficient use of existing and untapped agents in new indications.  Together, APNTâ„¢ and Optejet® have obvious synergies and thus a high potential to unlock a wide new range of ophthalmic therapeutics and applications.  We are keen to launch this collaboration as quickly as possible.”

Previous Post

Similis Bio Partners With Novel351k to Develop Multiple Biosimilar Programs

Next Post

Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
OcyonBio Announces Biosimilar Solutions to Begin GMP Manufacturing in Puerto Rico

Oxford Expands Biomanufacturing Real Estate Platform with Purchase, Lease Back of GMP Facility

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In